secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2026-08-05T20:06:24+00:00
Accession:  0001628280-26-053319
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q2 revenue down 48% to $20M; wins govt contracts for autonomous labs at MIT, Caltech, Northwestern
--------------------------------------------------------------------------------

- Q2 revenue $20M vs $39M YoY; GAAP net loss from continuing ops ($57M) vs ($53M).
- Adjusted EBITDA ($36M) vs ($25M); cash and equivalents $302M as of June 30.
- Won contracts to build autonomous labs at MIT, Caltech, Northwestern, U of Maryland under NSF's ~$400M cloud lab network.
- New ADME-One service claims 10X cost advantage over WuXi, signed 17 customers in first 6 weeks.
- Reaffirms FY 2026 total cash burn guidance of ($150)-($125)M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828026053319/0001628280-26-053319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828026053319/dna-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer